28
Participants
Start Date
July 31, 2003
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
Imatinib Mesylate (Gleevec)
300 mg orally twice daily
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Novartis
INDUSTRY
M.D. Anderson Cancer Center
OTHER